Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 69.18 USD -5.66% Market Closed
Market Cap: 12.5B USD

Insmed Inc
Investor Relations

Insmed Inc., a biopharmaceutical company rooted in Bridgewater, New Jersey, emerged from the desire to tackle serious and rare diseases with potentially groundbreaking therapies. The company's journey is defined by its commitment to developing novel treatments for patients suffering from conditions often overlooked by mainstream pharmaceutical firms. At the heart of Insmed's operations lies its pursuit of treatments for rare pulmonary diseases, with its flagship product, ARIKAYCE, exemplifying their mission in action. Approved by the FDA for treating Mycobacterium avium complex (MAC) lung disease, ARIKAYCE represents a significant breakthrough, addressing a critical unmet medical need. By targeting specific patient populations with limited options, Insmed taps into niche markets where they face less competition and, simultaneously, a profound opportunity to make a meaningful impact on patient lives.

The company's strategy revolves around leveraging innovative science to build a pipeline rich with potential treatments across various stages of clinical development. It focuses on expanding the use of ARIKAYCE, while also exploring new formulations and indications. Insmed channels resources into research and development, securing patent protections and establishing a robust global presence to ensure its therapies reach the patients who need them. Revenues are primarily generated through product sales, with ARIKAYCE as the cornerstone, alongside strategic partnerships and collaborations that allow for shared expertise and resources. This business model positions Insmed not only as a healthcare provider but as a key player in the biopharmaceutical industry, striving to transform lives by bringing forth meaningful medical innovations.

Show more
Loading

Earnings Calls

2024 Q3
Dec 23, 2024
Show Transcript
Previous
Next
Strong growth and cost reductions signal potential recovery for Xcel Brands.
2024 Q3
Dec 23, 2024

Xcel Brands reported a challenging third quarter, with revenues down to $1.9 million, driven by the sale of the Lori Goldstein brand. However, non-GAAP earnings improved by 56% year-over-year, highlighting strategic cost reductions, which have cut operating expenses by 50% to $2.8 million. The C. Wonder brand thrived with 60% retail sales growth despite hurricane disruptions, while Judith Ripka saw near 500% yearly growth in royalties. Management anticipates a positive trend in adjusted EBITDA moving into the fourth quarter and expects increased revenues in 2025 from new brands and a solid fourth quarter performance as postponed sales are realized.

Show Full Analysis

Management

Mr. William H. Lewis J.D., M.B.A.
President, CEO & Chairman
No Bio Available
Ms. Sara M. Bonstein M.B.A.
Chief Financial Officer
No Bio Available
Mr. John Drayton Wise M.B.A.
Chief Commercial Officer
No Bio Available
Mr. Brian K. Kaspar Ph.D.
Chief Scientific Officer
No Bio Available
Ms. Eleanor Barisser
Associate Director of Investor Relations
No Bio Available
Mandy Fahey
Executive Director of Corporate Communications
No Bio Available
Mr. Neil Hughes
GM & Head of Europe, Middle East and Africa
No Bio Available
Dr. Kevin Mange M.D.
Head of Clinical Development
No Bio Available
Dr. Paul D. Streck M.D.
Advisor
No Bio Available

Contacts

Address
NEW JERSEY
Bridgewater
700 Us Highway 202/206
Contacts
+19089779900.0
insmed.com